https://www.selleckchem.com/pr....oducts/oxalacetic-ac
th outcomes including new ADL and IADL dependency and mortality 1 year after discharge among older hospitalized patients.Emerging evidence indicates that A1 reactive astrocytes play crucial roles in the pathogenesis of Parkinson's disease (PD). Thus, development of agents that could inhibit the formation of A1 reactive astrocytes could be used to treat PD. Simvastatin has been touted as a potential neuroprotective agent for neurologic disorders such as PD, but the specific underlying mechanism remains unclear. The 1-methyl-4-phe